Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ophthotech in-licenses volociximab for ophthalmic uses

Biogen Idec (NASDAQ:BIIB) and PDL (NASDAQ:PDLI) granted Ophthotech (Princeton, N.J.)

Read the full 105 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE